Therefore, it is tempting to speculate that the expression of TRPML2 in this selected set of tissues may be able to prevent gross consequences of TRPML1 loss of function and spare some aspects of immune function in patients with MLIV. The gene discussed is MCOLN2; the disease is mucolipidosis type IV.